Q3 2024 Absci Corp Earnings Call Transcript
Key Points
- Absci Corp (ABSI) achieved a significant milestone in its collaboration with AstraZeneca by delivering AI-designed antibody sequences within six months.
- The company announced a new partnership with Twist Bioscience to design a novel antibody using generative AI, expanding its collaborative network.
- Absci Corp (ABSI) plans to initiate Phase 1 clinical studies of its ABS-101 program in the first half of 2025, with an interim data readout expected in the second half of 2025.
- The company has a robust pipeline of proprietary programs, including ABS-101, ABS-201, and ABS-301, all generated using its integrated drug creation platform.
- Absci Corp (ABSI) ended the quarter with $127.1 million in cash, cash equivalents, and short-term investments, providing a strong financial position to fund operations into the first half of 2027.
- Revenue for the third quarter of 2024 was only $1.7 million, indicating limited income from partner programs.
- Research and development expenses increased significantly to $18 million, up from $11 million in the prior year period, driven by increased lab operations and stock compensation expenses.
- There was a slight delay in the ABS-301 program due to issues at the contract research organization (CRO), affecting the timeline for data readouts.
- The company experienced a decrease in cash, cash equivalents, and short-term investments from $145.2 million as of June 30, 2024, to $127.1 million by the end of the quarter.
- Absci Corp (ABSI) continues to rely heavily on partnerships for revenue, which may pose a risk if new partnerships are not secured as anticipated.
Good day, and thank you for standing by. Welcome to the Absci Q3 2024 business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Alex Khan, VP, Finance and Investor Relations. Please go ahead.
Thank you. Earlier today, Absci released financial and operating results for the quarter ended September 30 2024. If you haven't received this news release or if you would like to be added to the company's distribution list, please send an email to [email protected]. An archived webcast of this call will be available for replay on Absci's Investor Relations website at investors.absci.com for at least 90 days after this call.
Joining me today are Sean McClain, Absci's Founder and CEO, and Zach Jonasson, Chief Financial Officer and Chief Business Officer. Christian Stegmann, Absci's SVP of Drug Creation will also join for Q&A following prepared
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
